Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL

Exclusion Criteria

• •\- • Primary DLBCL arise in lymph nodes or other lymphatic tissues.
• •Primary central nervous system lymphoma or secondary central nervous system involvement, known primary mediastinal lymphoma.
• •A history of severe allergies or allergic reactions to humanized or murine monoclonal antibodies.
• •In the past five years, patients with other malignant tumors have undergone radical treatment, except for basal cell carcinoma of skin, squamous cell carcinoma of skin, carcinoma in situ of breast and carcinoma in situ of cervix. History of human immunodeficiency virus (HIV) infection and/or patients with acquired immunodeficiency syndrome are known
• •Patients with active hepatitis B or active hepatitis C. Patients who are positive for hepatitis B Surface Antigen (HBsAg) or hepatitis C Virus (HCV) antibodies at screening stage must pass further detection of hepatitis B Virus (HBV) DNA titer (no more than 2500 copies/mL or 1000 IU/mL) and HCV RNA (no more than the lower limit of the detection method) in the row. In addition to active hepatitis B or hepatitis C infections requiring treatment, group trials can be conducted. Hepatitis B carriers, stable hepatitis B (DNA titer should not be higher than 2500 copies/mL or 1000 IU/mL) after drug treatment, and cured hepatitis C patients can be enrolled in the group.
• •Patients with any active infections requiring systemic anti-infective treatment within 14 days of treatment.
• •Received systemic antineoplastic therapy within 28 days before treatment, including chemotherapy, immunotherapy, biotherapy (cancer vaccine, cytokines, or growth factors that control cancer), etc..
• •Received major surgery within 28 days before treatment or radiotherapy within 90 days before treatment.
• •Received live vaccination (except influenza attenuated vaccine) within 28 days before treatment.
• •Patients requiring long-term systemic glucocorticoid therapy or other immunosuppressive therapy (\>prednisone 10mg/qd or equivalent dose of other glucocorticoid therapy). Allowing subjects to use local, ocular, intra-articular, intranasal and inhaled glucocorticoid therapy.
• •Patients suffering from uncontrollable comorbid diseases, including but not limited to symptomatic congestive heart failure, uncontrollable hypertension, unstable angina, active peptic ulcer or bleeding disorders.
• •Pregnant or lactating women.
• •Patients with a history of interstitial lung disease or non-infectious pneumonia. Subjects who have previously had drug-induced or radioactive non-infectious pneumonia but asymptomatic are allowed to enroll.
• •Any life-threatening disease, physical condition or organ dysfunction according to the researchers' judgment may endanger the safety of the subject or put the clinical research at excessive risk.